Search research articles
Contact Us
Filters
Showing results (41-50 of 55) with videos related to
Page
of 6
Sort By:
The Journal of Antimicrobial Chemotherapy
|
January 18, 2022
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
Ed J Gane, Christian Schwabe, Elina Berliba, et al.
Antiviral Therapy
|
January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants
Liviawati S Wu, Yue Hu, Edward J Gane, et al.
Antiviral Therapy
|
May 18, 2023
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults
Wim Pierson, Marianne Tuefferd, Florence Herschke, et al.
The Lancet. Gastroenterology & Hepatology
|
November 13, 2019
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Man-Fung Yuen, Kosh Agarwal, Edward J Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 4, 2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection
Zobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV
Kelong Han, Paul Benn, Jörg Sievers, et al.
Gastroenterology
|
January 10, 2019
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Man Fung Yuen, Edward J Gane, Dong Joon Kim, et al.
Nature Medicine
|
August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Gerald F Watts, Christian Schwabe, Russell Scott, et al.
Annals of the Rheumatic Diseases
|
March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
NEJM Evidence
|
February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Daniel Gaudet, Peter Clifton, David Sullivan, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 55) with videos related to
Sort By:
Page
of 6
The Journal of Antimicrobial Chemotherapy
|
January 18, 2022
Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection
Ed J Gane, Christian Schwabe, Elina Berliba, et al.
Antiviral Therapy
|
January 24, 2023
Population pharmacokinetic/pharmacodynamic models of JNJ-64794964, a toll-like receptor 7 agonist, in healthy adult participants
Liviawati S Wu, Yue Hu, Edward J Gane, et al.
Antiviral Therapy
|
May 18, 2023
A single, oral dose of the TLR7 agonist JNJ-64794964 induces transcriptomic and phenotypic changes in peripheral immune cells in healthy adults
Wim Pierson, Marianne Tuefferd, Florence Herschke, et al.
The Lancet. Gastroenterology & Hepatology
|
November 13, 2019
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial
Man-Fung Yuen, Kosh Agarwal, Edward J Gane, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
|
August 4, 2019
Long-term Benefits of Sustained Virologic Response for Patient-Reported Outcomes in Patients With Chronic Hepatitis C Virus Infection
Zobair M Younossi, Maria Stepanova, Andrei Racila, et al.
Clinical Pharmacology in Drug Development
|
April 29, 2025
A Randomized Phase 1 Study Evaluating Pharmacokinetics, Safety, and Tolerability of a High-Concentration, Long-Acting Cabotegravir Formulation in Adults Without HIV
Kelong Han, Paul Benn, Jörg Sievers, et al.
Gastroenterology
|
January 10, 2019
Antiviral Activity, Safety, and Pharmacokinetics of Capsid Assembly Modulator NVR 3-778 in Patients with Chronic HBV Infection
Man Fung Yuen, Edward J Gane, Dong Joon Kim, et al.
Nature Medicine
|
August 25, 2023
RNA interference targeting ANGPTL3 for triglyceride and cholesterol lowering: phase 1 basket trial cohorts
Gerald F Watts, Christian Schwabe, Russell Scott, et al.
Annals of the Rheumatic Diseases
|
March 24, 2019
Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study
Sudha Visvanathan, Stefan Daniluk, Rafał Ptaszyński, et al.
NEJM Evidence
|
February 6, 2024
RNA Interference Therapy Targeting Apolipoprotein C-III in Hypertriglyceridemia
Daniel Gaudet, Peter Clifton, David Sullivan, et al.
Page
of 6